Journal
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
Volume 12, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40164-023-00445-8
Keywords
-
Categories
Ask authors/readers for more resources
Researchers established acquired resistance to pinometostat in pediatric KMT2A::AFF1+ B-ALL cells, finding that resistant cells became less dependent on DOT1L-mediated H3K79 methylation but still relied on the physical presence of DOT1L, HOXA9, and the KMT2A::AFF1 fusion. Furthermore, these cells lost epigenetic regulation and expression of certain KMT2A-fusion target genes, while other target genes remained unaffected.
In KMT2A-rearranged acute lymphoblastic leukemia (ALL), an aggressive malignancy, oncogenic KMT2A-fusion proteins inappropriately recruit DOT1L to promote leukemogenesis, highlighting DOT1L as an attractive therapeutic target. Unfortunately, treatment with the first-in-class DOT1L inhibitor pinometostat eventually leads to non-responsiveness. To understand this we established acquired pinometostat resistance in pediatric KMT2A::AFF1+ B-ALL cells. Interestingly, these cells became mostly independent of DOT1L-mediated H3K79 methylation, but still relied on the physical presence of DOT1L, HOXA9 and the KMT2A::AFF1 fusion. Moreover, these cells selectively lost the epigenetic regulation and expression of various KMT2A-fusion target genes such as PROM1/CD133, while other KMT2A::AFF1 target genes, including HOXA9 and CDK6 remained unaffected. Concomitantly, these pinometostat-resistant cells showed upregulation of several myeloid-associated genes, including CD33 and LILRB4/CD85k. Taken together, this model comprehensively shows the adaptive potential of KMT2A-rearranged ALL cells upon losing dependency on one of its main oncogenic properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available